SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Rosalia de Necochea-Campion, Carlos J. Diaz Osterman, Heng-Wei Hsu, Junjie Fan, Saied Mirshahidi, Nathan R. Wall, Chien-Shing Chen, AML sensitivity to YM155 is modulated through AKT and Mcl-1, Cancer Letters, 2015,

    CrossRef

  2. 2
    M. Batinica, B. Akgül, S. Silling, C. Mauch, P. Zigrino, Correlation of Merkel cell polyomavirus positivity with PDGFRα mutations and survivin expression in Merkel cell carcinoma, Journal of Dermatological Science, 2015, 79, 1, 43

    CrossRef

  3. 3
    L Zhang, W Zhang, Y-F Wang, B Liu, W-F Zhang, Y-F Zhao, A B Kulkarni, Z-J Sun, Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma, Cell Death and Disease, 2015, 6, 5, e1771

    CrossRef

  4. 4
    Kohsuke Shakushiro, Hiroki Kawano, Mari Nakata, Aya Kita, Atsushi Maeda, Shunsuke Watanabe, Kazuhiro Sako, Naoto Oku, Formulation Design and Evaluation of Liposomal Sepantronium Bromide (YM155), a Small-Molecule Survivin Suppressant, Based on Pharmacokinetic Modeling and Simulation, Pharmaceutical Research, 2015, 32, 1, 238

    CrossRef

  5. 5
    Jingcao Huang, Hui Lyu, Jianxiang Wang, Bolin Liu, Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia, Cancer Letters, 2015,

    CrossRef

  6. 6
    S M Cheng, Y C Chang, C Y Liu, J Y C Lee, H H Chan, C W Kuo, K Y Lin, S L Tsai, S H Chen, C F Li, E Leung, J R Kanwar, C C Huang, J Y Chang, C H A Cheung, YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells, British Journal of Pharmacology, 2015, 172, 1
  7. 7
    Bill H Chang, Kara Johnson, Dorian LaTocha, Joelle S J Rowley, Jade Bryant, Russell Burke, Rebecca L Smith, Marc Loriaux, Markus Müschen, Charles Mullighan, Brian J Druker, Jeffrey W Tyner, YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway, Journal of Hematology & Oncology, 2015, 8, 1

    CrossRef

  8. 8
    Marzia Pennati, Stefania Sbarra, Michelandrea De Cesare, Alessia Lopergolo, Silvia L. Locatelli, Elisa Campi, Maria Grazia Daidone, Carmelo Carlo-Stella, Alessandro M. Gianni, Nadia Zaffaroni, YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation, International Journal of Cancer, 2015, 136, 2
  9. 9
    Hiroki Kawano, Kohsuke Shakushiro, Mari Nakata, Aya Kita, Atsushi Maeda, Shunsuke Watanabe, Kazuhiro Sako, Naoto Oku, Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant, European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 1, 283

    CrossRef

  10. 10
    Douglas B. Kell, Stephen G. Oliver, How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion, Frontiers in Pharmacology, 2014, 5,

    CrossRef

  11. 11
    Yu-Fan Wang, Wei Zhang, Ke-Fei He, Bing Liu, Lu Zhang, Wen-Feng Zhang, Ashok B. Kulkarni, Yi-Fang Zhao, Zhi-Jun Sun, Induction of autophagy-dependent cell death by the survivin suppressant YM155 in salivary adenoid cystic carcinoma, Apoptosis, 2014, 19, 4, 748

    CrossRef

  12. 12
    Sharad Sharma, Hang-Ping Yao, Yong-Qing Zhou, Jianwei Zhou, Ruiwen Zhang, Ming-Hai Wang, Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics, Molecular Oncology, 2014, 8, 3, 469

    CrossRef

  13. 13
    Dah-Renn FU, Daiki KATO, Ai WATABE, Yoshifumi ENDO, Tsuyoshi KADOSAWA, Prognostic Utility of Apoptosis Index, Ki-67 and Survivin Expression in Dogs with Nasal Carcinoma Treated with Orthovoltage Radiation Therapy, Journal of Veterinary Medical Science, 2014, 76, 11, 1505

    CrossRef

  14. 14
    Anke Rauch, Dorle Hennig, Claudia Schäfer, Matthias Wirth, Christian Marx, Thorsten Heinzel, Günter Schneider, Oliver H. Krämer, Survivin and YM155: How faithful is the liaison?, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2014, 1845, 2, 202

    CrossRef

  15. 15
    S N Brun, S L Markant, L A Esparza, G Garcia, D Terry, J-M Huang, M S Pavlyukov, X-N Li, G A Grant, J R Crawford, M L Levy, E M Conway, L H Smith, I Nakano, A Berezov, M I Greene, Q Wang, R J Wechsler-Reya, Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma, Oncogene, 2014,

    CrossRef

  16. 16
    Kalliopi Ch. Athanasoula, Helen Gogas, Katerina Polonifi, Aristeidis G. Vaiopoulos, Aristidis Polyzos, Marina Mantzourani, Survivin beyond physiology: Orchestration of multistep carcinogenesis and therapeutic potentials, Cancer Letters, 2014, 347, 2, 175

    CrossRef

  17. 17
    N Purroy, P Abrisqueta, J Carabia, C Carpio, E Calpe, C Palacio, J Castellví, M Crespo, F Bosch, Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein, Leukemia, 2014, 28, 10, 1993

    CrossRef

  18. 18
    Heather M. Calderone, Akshita Dutta, Lauren Smith, Alexandra Eckardt, Ping Zhao, Giselle Saulnier Sholler, YM155 Inhibits Neuroblastoma Cell Migration and Survival <i>in Vitro</i> and Tumor Growth and Metastatic Burden in a Pre-Clinical Model, Journal of Cancer Therapy, 2014, 05, 13, 1289

    CrossRef

  19. 19
    Hidekazu Koike, Takashi Nitta, Yoshitaka Sekine, Seiji Arai, Yosuke Furuya, Masashi Nomura, Hiroshi Matsui, Yasuhiro Shibata, Kazuto Ito, Tetsunari Oyama, Kazuhiro Suzuki, YM155 reverses rapamycin resistance in renal cancer by decreasing survivin, Journal of Cancer Research and Clinical Oncology, 2014, 140, 10, 1705

    CrossRef

  20. 20
    Roser Mir, Elisabetta Stanzani, Fina Martinez-Soler, Alberto Villanueva, August Vidal, Enric Condom, Jordi Ponce, Joan Gil, Avelina Tortosa, Pepita Giménez-Bonafé, YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression, Gynecologic Oncology, 2014, 132, 1, 211

    CrossRef

  21. 21
    Pooja Hingorani, Paul Dickman, Pamela Garcia-Filion, Andrea White-Collins, Edward A. Kolb, David O. Azorsa, BIRC5 expression is a poor prognostic marker in Ewing sarcoma, Pediatric Blood & Cancer, 2013, 60, 1
  22. 22
    Naoki Kaneko, Aya Kita, Kentaro Yamanaka, Masamichi Mori, Combination of YM155, a survivin suppressant with a STAT3 inhibitor: A new strategy to treat diffuse large B-cell lymphoma, Leukemia Research, 2013, 37, 9, 1156

    CrossRef

  23. 23
    Darcy J. P. Bates, Lionel D. Lewis, Manipulating the apoptotic pathway: potential therapeutics for cancer patients, British Journal of Clinical Pharmacology, 2013, 76, 3
  24. 24
    Rodrigo Santa Cruz Guindalini, Maria Cecília Mathias Machado, Bernardo Garicochea, Monitoring Survivin Expression in Cancer: Implications for Prognosis and Therapy, Molecular Diagnosis & Therapy, 2013, 17, 6, 331

    CrossRef

  25. 25
    Darryl T. Martin, Christopher J. Hoimes, Hristos Z. Kaimakliotis, Christopher J. Cheng, Ke Zhang, Jingchun Liu, Marcia A. Wheeler, W. Kevin Kelly, Greg N. Tew, W. Mark Saltzman, Robert M. Weiss, Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer, Nanomedicine: Nanotechnology, Biology and Medicine, 2013, 9, 8, 1124

    CrossRef

  26. 26
    Yumiko Aoyama, Atsunori Kaibara, Akitsugu Takada, Tetsuya Nishimura, Masataka Katashima, Taiji Sawamoto, Population pharmacokinetic modeling of Sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma, Investigational New Drugs, 2013, 31, 2, 443

    CrossRef

  27. 27
    Mohane Selvaraj Coumar, Fang-Ying Tsai, Jagat Rakesh Kanwar, Sailu Sarvagalla, Chun Hei Antonio Cheung, Treat cancers by targeting survivin: Just a dream or future reality?, Cancer Treatment Reviews, 2013, 39, 7, 802

    CrossRef

  28. 28
    Yumiko Aoyama, Tetsuya Nishimura, Taiji Sawamoto, Taroh Satoh, Masataka Katashima, Kazuhiko Nakagawa, Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment, Cancer Chemotherapy and Pharmacology, 2012, 70, 3, 373

    CrossRef

  29. 29
    Tsuyoshi Minematsu, Takuya Sonoda, Tadashi Hashimoto, Megumi Iwai, Todd Oppeneer, Laurie Felder, Nobuaki Shirai, Aiji Miyashita, Takashi Usui, Pharmacokinetics, distribution and excretion of YM155 monobromide, a novel small-molecule survivin suppressant, in male and pregnant or lactating female rats, Biopharmaceutics & Drug Disposition, 2012, 33, 3
  30. 30
    R. Arora, M. Shuda, A. Guastafierro, H. Feng, T. Toptan, Y. Tolstov, D. Normolle, L. L. Vollmer, A. Vogt, A. Domling, J. L. Brodsky, Y. Chang, P. S. Moore, Survivin Is a Therapeutic Target in Merkel Cell Carcinoma, Science Translational Medicine, 2012, 4, 133, 133ra56

    CrossRef

  31. 31
    J W Tyner, A M Jemal, M Thayer, B J Druker, B H Chang, Targeting survivin and p53 in pediatric acute lymphoblastic leukemia, Leukemia, 2012, 26, 4, 623

    CrossRef

  32. 32
    Gabriela Nestal de Moraes, Paloma Silva Souza, Fernanda Casal de Faria Costas, Flavia Cunha Vasconcelos, Flaviana Ruade Souza Reis, Raquel Ciuvalschi Maia, The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia, Leukemia Research and Treatment, 2012, 2012, 1

    CrossRef

  33. 33
    Eugene Varfolomeev, Domagoj Vucic, Inhibitor of apoptosis proteins: fascinating biology leads to attractive tumor therapeutic targets, Future Oncology, 2011, 7, 5, 633

    CrossRef

  34. 34
    Haikuo Tang, Huanjie Shao, Chunrong Yu, Jinsong Hou, Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263, Biochemical Pharmacology, 2011, 82, 9, 1066

    CrossRef

  35. 35
    Roshni Kalachand, Bryan T. Hennessy, Maurie Markman, Molecular Targeted Therapy in Ovarian Cancer, Drugs, 2011, 71, 8, 947

    CrossRef

  36. 36
    Denis Drygin, CK2 as a Logical Target in Cancer Therapy: Potential for Combining CK2 Inhibitors with Various Classes of Cancer Therapeutic Agents,